|
1.
|
|
18 p, 862.2 KB |
Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma
/
Chari, Ajai (Mount Sinai School of Medicine, USA) ;
Askari, Elham (Hospital Universitario Fundación Jiménez Díaz) ;
Caers, Jo (Centre Hospitalier Universitaire de Liège, Belgium) ;
Costa, Luciano J. (University of Alabama at Birmingham, USA) ;
Hilder, Brandi W. (Janssen Research & Development, Spring House, USA) ;
Krishnan, Amrita (City of Hope Comprehensive Cancer Center, Duarte, USA) ;
Mateos, M. V (Hospital Universitario de Salamanca) ;
Minnema, Monique C. (University Utrecht, Netherlands) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Pillarisetti, Kodandaram (Janssen Research & Development, Spring House, USA) ;
Van De Donk, Niels W.C.J. (Vrije Universiteit Amsterdam, Netherlands) ;
Rodríguez-Otero, Paula (Clínica Universidad de Navarra)
What is this summary about? This plain language summary describes the results of a phase 1 research study (or clinical trial) called MonumenTAL-1 published in the New England Journal of Medicine in December 2022. [...]
2023 -  10.2217/fon-2023-0332
Future oncology (London, England), Vol. 19 Núm. 27 (september 2023) , p. 1823-1840
|
|
|
2.
|
|
11 p, 396.3 KB |
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma : A subanalysis of OPTIMISMM by clinical characteristics
/
Richardson, Paul G.. (Department of Medical Oncology. Harvard Medical School) ;
Schjesvold, Fredrik (University of Oslo) ;
Weisel, Katja (University Medical Center Hamburg-Eppendorf) ;
Moreau, Philippe (University Hospital Hôtel-Dieu) ;
Anderson, Larry D. (University of Texas Southwestern Medical Center) ;
White, Darrell (Dalhousie University and Queen Elizabeth II Health Sciences Centre) ;
Rodriguez-Otero, Paula (Clínica Universidad de Navarra) ;
Sonneveld, Pieter (Erasmus MC Cancer Institute) ;
Engelhardt, Monika (Universitätsklinikum Freiburg) ;
Jenner, Matthew (University Hospital Southampton NHS Foundation Trust (Regne Unit)) ;
Corso, Alessandro (Hospital of Legnano) ;
Dürig, Jan (University Hospital Essen (Alemanya)) ;
Pavic, Michel (Centre Hospitalier Universitaire De Sherbrooke) ;
Salomo, Morten (Copenhagen University Hospital) ;
Beksac, Meral (Ankara University) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Lindsay, Jindriska (East Kent Hospitals University NHS Foundation Trust) ;
Liberati, Anna Marina (University of Perugia) ;
Galli, Monica (Ospedale Papa Giovanni XXIII. U.O. di Ematologia) ;
Robak, Pawel (Medical University of Lodz) ;
Larocca, Alessandra (A.O.U. Citta della Salute e della Scienza di Torino) ;
Yagci, Munci (Gazi University Medical Faculty) ;
Vural, Filiz (Ege University) ;
Kanate, Abraham (West Virginia University) ;
Jiang, Ruiyun (Bristol Myers Squibb) ;
Grote, Lara (Bristol Myers Squibb) ;
Peluso, Teresa (Celgene International Sàrl. a Bristol-Myers Squibb Company) ;
Dimopoulos, Meletios (National and Kapodistrian University of Athens)
Objective: We evaluated the efficacy and safety of pomalidomide, bortezomib, and dexamethasone (PVd) vs bortezomib and dexamethasone (Vd) by age, renal function, and high-risk cytogenetic abnormalities in lenalidomide-pretreated patients with multiple myeloma at first relapse. [...]
2022 - 10.1111/ejh.13706
European Journal of Haematology, Vol. 108 Núm. 1 (january 2022) , p. 73-83
|
|
|
3.
|
|
4 p, 756.5 KB |
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma : final analysis of PLEIADES and EQUULEUS
/
Moreau, Philippe (Hematology. University Hospital Hôtel-Dieu, France) ;
Chari, Ajai (Icahn School of Medicine at Mount Sinai, New York, USA) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Martínez-López, Joaquín (Hospital Universitario 12 de Octubre (Madrid)) ;
Haenel, M. (Klinikum Chemnitz, Germany) ;
Touzeau, Cyrille (University Hospital Hôtel-Dieu, France) ;
Ailawadhi, Sikander (Mayo Clinic Florida, USA) ;
Besemer, Britta (Universitaetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Germany) ;
de la Rubia Comos, Javier (Catholic University of Valencia) ;
Encinas, Cristina (Hospital General Universitario Gregorio Marañón) ;
Mateos, M. V (Hospital Universitario de Salamanca) ;
Salwender, Hans (AK Altona and AK St. Georg, Hamburg, Germany) ;
Rodriguez-Otero, Paula (Clínica Universidad de Navarra) ;
Hulin, Cyrille (Hôpital Haut Lévêque. University Hospital, Pessac, France) ;
Karlin, Lionel (Centre Hospitalier Lyon Sud. Hospices Civils de Lyon, France) ;
Sureda Balari, Anna (Institut d'Investigació Biomèdica de Bellvitge) ;
Bargay, Joan (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Benboubker, Lotfi (Centre Hospitalier Régional Universitaire (CHRU), France) ;
Rosiñol, Laura (Hospital Clínic i Provincial de Barcelona) ;
Tarantolo, Stefano (Nebraska Cancer Specialists, Omaha, USA) ;
Terebelo, Howard (Providence Cancer Center, Southfield, USA) ;
Yang, Shiyi (Janssen Research & Development. LLC, USA) ;
Wang, Jianping (Janssen Research & Development. LLC, USA) ;
Nnane, Ivo (Janssen Research & Development. LLC, USA) ;
Qi, Ming (Janssen Research & Development. LLC, USA) ;
Kosh, Michele (Janssen Research & Development. LLC, USA) ;
Delioukina, Maria (Janssen Research & Development. LLC, USA) ;
Goldschmidt, Hartmut (GMMG-Study Group at University Hospital Heidelberg, Germany)
2023 - 10.1038/s41408-023-00805-x
Blood Cancer Journal, Vol. 13 Núm. 1 (march 2023)
|
|
|
4.
|
|
8 p, 1.1 MB |
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
/
Encinas, Cristina (Hospital General Universitario Gregorio Marañón (HGUGM). IiSGM) ;
Hernandez-Rivas, José-Ángel (Hospital Universitario Infanta Leonor) ;
Oriol, Albert (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Rosiñol, Laura (Hospital Clínic i Provincial de Barcelona. CIBERONC) ;
Blanchard, María Jesús (Hospital Universitario Ramón y Cajal (Madrid)) ;
Bellón, José-María (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM)) ;
García-Sanz, Ramón (Hospital Universitario de Salamanca (IBSAL). CIBERONC e Instituto de Investigación del Cáncer de Salamanca-IBMCC (USAL-CSIC)) ;
de la Rubia, Javier (Hospital Universitari Doctor Peset (València)) ;
López de la Guía, Ana (Hospital Universitario La Paz (Madrid)) ;
Jímenez-Ubieto, Ana (Hospital Universitario 12 de Octubre (Madrid)) ;
Jarque, Isidro (Hospital Universitario la Fe. CIBERONC) ;
Iñigo, Belén (Hospital Clínico San Carlos (Madrid)) ;
Dourdil, Victoria (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
De Arriba, Felipe (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Cuéllar Pérez-Ávila, Clara (Hospital Universitario 12 de Octubre (Madrid)) ;
Gonzalez, Yolanda (Hospital Universitari de Girona Doctor Josep Trueta) ;
Hernández, Miguel-Teodoro (Hospital Universitario de Canarias (La Laguna)) ;
Bargay, Joan (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Granell, Miquel (Institut d'Investigació Biomèdica Sant Pau) ;
Rodríguez-Otero, Paula (Clínica Universitaria de Navarra. CIMA. IDISNA. CIBERONC) ;
Silvent, Maialen (Hospital de Donostia (Sant Sebastià, País Basc)) ;
Cabrera, Carmen (Complejo Hospitalario de Cáceres) ;
Rios, Rafael (Hospital Universitario Virgen de las Nieves (Granada)) ;
Alegre, Adrián (Hospital Universitario de la Princesa. Hospital Universitario Quirónsalud) ;
Gironella, Mercedes (Hospital Universitari Vall d'Hebron) ;
Gonzalez, Marta-Sonia (Hospital Universitario de Santiago) ;
Sureda, Anna (Institut Català d'Oncologia) ;
Sampol, Antonia (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Ocio, Enrique M. (Hospital Universitario Marqués de Valdecilla. (IDIVAL). Universidad de Cantabria) ;
Krsnik, Isabel (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
García, Antonio (Hospital Arnau de Vilanova (Lleida, Catalunya)) ;
García-Mateo, Aránzazu (Hospital General de Segovia) ;
Soler, Joan-Alfons (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Martín Sánchez, Jesús (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Arguiñano, José M (Complejo Hospitalario de Navarra) ;
Mateos, M. V. (Instituto de Investigación Biomédica de Salamanca) ;
Bladé Creixenti, Juan (Hospital Clínic i Provincial de Barcelona. CIBERONC) ;
San-Miguel, J (Clínica Universitaria de Navarra. CIMA. IDISNA; CIBERONC) ;
Lahuerta, J. J (Hospital Universitario 12 de Octubre (Madrid)) ;
Martínez-López, Joaquín (Hospital Universitario 12 de Octubre (Madrid))
Infections remain a common complication in patients with multiple myeloma (MM) and are associated with morbidity and mortality. A risk score to predict the probability of early severe infection could help to identify the patients that would benefit from preventive measures. [...]
2022 - 10.1038/s41408-022-00652-2
Blood Cancer Journal, Vol. 12 Núm. 4 (april 2022) , p. 68
|
|
|
5.
|
|
10 p, 306.4 KB |
Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone : analyses from the Phase II HORIZON study
/
Larocca, Alessandra (Azienda Ospedaliero - Universitaria Città della Salute e della Scienza) ;
Leleu, Xavier (CHU de Poitiers) ;
Touzeau, Cyrille (Université d'Angers) ;
Bladé Creixenti, Juan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Paner, Agne (Rush University Medical Center) ;
Mateos, M. V (Instituto de Investigación Biomédica de Salamanca) ;
Cavo, Michele (Bologna University School of Medicine) ;
Maisel, Christopher (Baylor Scott & White Charles A) ;
Alegre, Adrian (Hospital Universitario de la Princesa (Madrid)) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Raptis, Anastasios (niversity of Pittsburgh School of Medicine) ;
Rodriguez-Otero, Paula (Clínica Universidad de Navarra) ;
Mazumder, Amitabha (The Oncology Institute of Hope and Innovation) ;
Laubach, Jacob (Harvard Medical School) ;
Nadeem, Omar (Harvard Medical School) ;
Sandberg, Anna (Oncopeptides AB (Suècia)) ;
Orre, Marie (Oncopeptides AB (Suècia)) ;
Torrång, Anna (SDS Life Science (Suècia)) ;
Bakker, Nicolaas A (Oncopeptides AB) ;
Richardson, Paul G.. (Harvard Medical School) ;
Universitat Autònoma de Barcelona
Relapsed/refractory multiple myeloma (RRMM) is known to have a high burden of disease and complications associated with refractoriness to prior lines of therapy. Severe pain and fatigue symptoms and impairments in physical and emotional functioning have been strongly linked to reduced health-related quality of life (HRQoL) in patients with RRMM. [...]
2022 - 10.1111/bjh.17887
British Journal of Haematology, Vol. 196 Núm. 3 (february 2022) , p. 639-648
|
|
|
6.
|
|
9 p, 1.1 MB |
Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma
/
Tamariz-Amador, Luis-Esteban (Clínica Universidad de Navarra) ;
Rodríguez-Otero, Paula (Clínica Universidad de Navarra) ;
Jiménez-Ubieto, Ana (Hospital Universitario 12 de Octubre (Madrid)) ;
Rosiñol, Laura (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ríos-Tamayo, Rafael (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Sureda, Anna (Hospital Duran i Reynals (Hospitalet del Llobregat)) ;
Blanchard, María Jesús (Hospital Universitario Ramón y Cajal (Madrid)) ;
Hernández, Miguel Teodoro (Hospital Universitario de Canarias (La Laguna)) ;
Cabañas Perianes, Valentín (Hospital Universitario Virgen de la Arrixaca (Múrcia)) ;
Jarque, Isidro (Hospital Universitari i Politècnic La Fe (València)) ;
Bargay, Joan (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Gironella, Mercedes (Hospital Universitari Vall d'Hebron) ;
De Arriba, Felipe (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Palomera, Luis (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Blanchard (Hospital Universitari de Girona Doctor Josep Trueta) ;
Martí, José M. (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ;
Krsnik, Isabel (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Arguiñano, José M. (Hospital Universitario de Navarra) ;
González, Maríua Ester (Hospital Universitario de Cabueñes (Gijón)) ;
Casado Montero, Luis Felipe (Hospital Virgen de la Salud (Toledo)) ;
González-Rodriguez, Ana Pilar (Hospital Universitario Central de Asturias) ;
López-Anglada, Lucía (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Puig, Noemí (Hospital Universitario de Salamanca) ;
Cedena, María Teresa (Hospital Universitario 12 de Octubre (Madrid)) ;
Paiva, Bruno (Clínica Universidad de Navarra) ;
Mateos, M. V (Instituto de Investigación Biomédica de Salamanca) ;
San-Miguel, J (Clínica Universidad de Navarra) ;
Lahuerta, J. J (Hospital Universitario 12 de Octubre (Madrid)) ;
Bladé Creixenti, Juan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Trocóniz, Iñaki F. (Universidad de Navarra) ;
Universitat Autònoma de Barcelona
Introduction: Response kinetics is a well-established prognostic marker in acute lymphoblastic leukemia. The situation is not clear in multiple myeloma (MM) despite having a biomarker for response monitoring (monoclonal component [MC]). [...]
2022 - 10.1016/j.clml.2022.04.024
Clinical Lymphoma, Myeloma & Leukemia, Vol. 22 Núm. 9 (september 2022) , p. e844-e852
|
|
|
7.
|
|
13 p, 449.0 KB |
Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma
/
Richardson, Paul G.. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Harvard Medical School) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Larocca, Alessandra (Università di Torino. Azienda Ospedaliero-Universitaria Città della Salute e della Scienza) ;
Bladé Creixenti, Juan (Hospital Clínic i Provincial de Barcelona) ;
Cavo, Michele (Seràgnoli Institute of Hematology. Bologna University School of Medicine) ;
Rodriguez-Otero, Paula (Clínica Universidad de Navarra) ;
Leleu, Xavier (CHU de Poitiers) ;
Nadeem, Omar (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Harvard Medical School) ;
Hiemenz, John W. (Division of Hematology-Oncology. Department of Medicine. University of Florida) ;
Hassoun, Hani (Memorial Sloan Kettering Cancer Center) ;
Touzeau, Cyrille (Université de Nantes) ;
Alegre, Adrian (Hospital Universitario de la Princesa (Madrid)) ;
Paner, Agne (Rush University Medical Center) ;
Maisel, Christopher (Baylor Scott & White Charles A. Sammons Cancer Center) ;
Mazumder, Amitabha (Oncology Institute of Hope and Innovation) ;
Raptis, Anastasios (Universityof Pittsburgh School of Medicine) ;
Moreb, Jan S. (Novant Health Hematology. Novant Health Forsyth Medical Center) ;
Anderson, Kenneth C. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Harvard Medical School) ;
Laubach, Jacob P. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Harvard Medical School) ;
Thuresson, Sara (Oncopeptides AB) ;
Thuresson, Marcus (Oncopeptides AB) ;
Byrne, Catriona (Oncopeptides AB) ;
Harmenberg, Johan (Oncopeptides AB) ;
Bakker, Nicolaas A. (Oncopeptides AB) ;
Mateos, M. V (Hospital Clínico Universitario (Salamanca))
PURPOSE Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate that targets aminopeptidases and rapidly and selectively releases alkylating agents into tumor cells. The phase II HORIZON trial evaluated the efficacy of melflufen plus dexamethasone in relapsed and refractory multiple myeloma (RRMM), a population with an important unmet medical need. [...]
2021 - 10.1200/JCO.20.02259
Journal of Clinical Oncology, Vol. 39 Núm. 7 (january 2021) , p. 757-767
|
|
|
8.
|
|
6 p, 359.1 KB |
Predicting long-term disease control in transplant-ineligible patients with multiple myeloma : impact of an MGUS-like signature
/
Rodriguez-Otero, Paula (Clínica Universidad de Navarra. Centro de Investigación Médica Aplicada) ;
Mateos, M. V (Complejo Asistencial Universitario de Salamanca. Instituto de Investigación Biomédica de Salamanca) ;
Martínez-López, Joaquín (Hospital Universitario 12 de Octubre (Madrid)) ;
Hernández, Miguel Teodoro (Hospital Universitario de Canarias (La Laguna)) ;
Ocio, E. M. (Complejo Asistencial Universitario de Salamanca. Instituto de Investigación Biomédica de Salamanca) ;
Rosiñol, Laura (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Martínez Martínez, Rafael (Hospital Clínico San Carlos (Madrid)) ;
Teruel, Ana Isabel (Hospital Clínic Universitari (València)) ;
Gutiérrez, Norma C. (Complejo Asistencial Universitario de Salamanca. Instituto de Investigación Biomédica de Salamanca) ;
Bargay, Joan (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Bengoechea, Enrique (Hospital Universitario de Donostia (Sant Sebastià, País Basc)) ;
González, Yolanda (Hospital Universitari de Girona Doctor Josep Trueta) ;
Perez de Oteyza, Jaime (Hospital Universitario HM Sanchinarro (Madrid)) ;
Gironella, Mercedes (Hospital Universitari Vall d'Hebron) ;
Nuñez-Córdoba, Jorge (Research Support Service. Central Clinical Trials Unit. University Clinic of Navarra) ;
Encinas, Cristina (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM)) ;
Martín, Jesús (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Cabrera, Carlos (Hospital San Pedro de Alcántara) ;
Palomera, Luis (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
De Arriba, Felipe (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Cedena, María Teresa (Hospital Universitario 12 de Octubre (Madrid)) ;
Puig, N. (Complejo Asistencial Universitario de Salamanca. Instituto de Investigación Biomédica de Salamanca) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Paiva, Bruno (Clínica Universidad de Navarra. Centro de Investigación Médica Aplicada) ;
Bladé Creixenti, Juan (Hospital Clínico San Carlos (Madrid)) ;
Lahuerta, J. J. (Hospital Universitario de Canarias (La Laguna)) ;
San Miguel, J. F. (Clínica Universidad de Navarra. Centro de Investigación Médica Aplicada) ;
Universitat Autònoma de Barcelona
Disease control at 5 years would be a desirable endpoint for elderly multiple myeloma (MM) patients, but biomarkers predicting this are not defined. Therefore, to gain further insights in this endpoint, a population of 498 newly diagnosed transplant-ineligible patients enrolled in two Spanish trials (GEM2005MAS65 and GEM2010MAS65), has been analyzed. [...]
2019 - 10.1038/s41408-019-0176-x
Blood Cancer Journal, Vol. 9 Núm. 4 (january 2019) , p. 36
|
|
|
9.
|
|
11 p, 1.3 MB |
Melflufen for relapsed and refractory multiple myeloma
/
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Larocca, Alessandra (Azienda Ospedaliero-Universitaria Città Della Salute E Della Scienza Di Torino. University of Torino) ;
Leleu, Xavier (Department of Hematology. CHU De Poitiers) ;
Hájek, R (Department of Hemato-Oncology. University of Ostrava and Faculty of Medicine. University of Ostrava) ;
Hassoun, Hani (Memorial Sloan Kettering Cancer Center) ;
Rodríguez-Otero, P. (Clínica Universidad de Navarra) ;
Paner, A. (Division of Hematology. Oncology and Stem Cell Transplant. Rush University Medical Center) ;
Schjesvold, F. H. (Oslo Myeloma Center. Oslo University Hospital and K.G. Jebsen Centre for B-Cell Malignancies. University of Oslo) ;
Gullbo, J. (Department of Medical Sciences. Division of Clinical Pharmacology. Uppsala University) ;
Richardson, Paul G.. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Jerome Lipper Multiple Myeloma Center) ;
Universitat Autònoma de Barcelona
Introduction: The overall survival of patients with multiple myeloma has improved with the advent of novel agents; however, multiple myeloma remains incurable. Combinations of standard-of-care agents such as immunomodulators, proteasome inhibitors, and anti-CD38 monoclonal antibodies are increasingly used in earlier lines of therapy. [...]
2020 - 10.1080/13543784.2020.1808884
Expert Opinion on Investigational Drugs, Vol. 29 Núm. 10 (february 2020) , p. 1069-1078
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
